The PubMed record documents an observational comparative analysis titled “Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.” The work aims to evaluate outcomes following CAR T-Cell Therapy in two distinct lymphoma cohorts: patients with transformed indolent Non-Hodgkin Lymphomas and patients with de novo DLBCL. The study is presented under the multicenter Italian CAR T-SIE study umbrella.
The PubMed entry classifies the report as an observational study and indicates a multicenter Italian collaboration with authors and contributors from numerous hematology and oncology centers across Italy. Beyond that classification and the multicenter nature implied by author affiliations, the public record accessed here does not contain details on study design elements such as inclusion/exclusion criteria, sample size, CAR T products administered, conditioning regimens, endpoints, follow-up duration, or statistical approaches.
The article lists Nicole Fabbri as first author with a long author list (Nicole Fabbri et al.) and includes contributors from many Italian institutions. Affiliations named in the PubMed record include, among others, the University of Bologna, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Fondazione IRCCS Istituto Nazionale dei Tumori (Milano), Sapienza University (Rome), Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome), San Raffaele Scientific Institute (Milan), University Hospital Torino, and multiple regional hematology units. The corresponding author’s email address is provided in the full record metadata on PubMed.
These bibliographic elements permit locating the full-text article through the journal or publisher and verifying authorship and provenance.
The PubMed content provided for this exercise does not include the article abstract, results, discussion, or supplementary material. Consequently, the following critical items are not reported in the available source text and cannot be inferred:
Because these items are absent from the scraped PubMed page content used here, any clinical or numeric statements about efficacy, safety, or comparative advantage would be speculative and are therefore not included.
The title and study type indicate that the paper addresses an important clinical question: how outcomes with CAR T-Cell Therapy compare between patients with transformed indolent NHL and those with de novo DLBCL. This is clinically relevant because transformed indolent lymphoma and de novo DLBCL may differ in biology, prior therapies, and prognosis, which can affect response to cellular therapies.
However, because the abstract and results are not present in the PubMed fragment reviewed, clinicians and researchers should not rely on this record for clinical decision-making or for citation of efficacy or safety data. Instead, they should retrieve the full-text article via the journal (Eur J Cancer), the DOI, or institutional access to examine methods, results, and authors’ interpretations before applying findings to practice or research planning.
To obtain the complete study data, methods, and authors’ conclusions, consult the full-text article in European Journal of Cancer using the DOI 10.1016/j.ejca.2026.116879 or the PubMed PMID 42302353. The PubMed entry provides a link to full text options (publisher site) where the abstract and full article should be available. If institutional access is restricted, consider contacting the corresponding author or using interlibrary loan or document delivery services.
Note on this summary
This rewritten clinical summary is strictly limited to the bibliographic and metadata information present in the provided PubMed page content. The source text did not include the abstract, numerical outcomes, or the manuscript body; those items are explicitly noted as unavailable here and therefore are not reported or interpreted in this summary.